Abstract:Botulinum neurotoxins (BoNTs), ricin, and many other biological toxins are called AB toxins possessing heterogeneous A and B subunits. We propose herein a quick and safe sensing approach to AB toxins based on their unique quaternary structures. The proposed approach utilizes IgG antibodies against their A-subunits in combination with those human cell-membrane glycolipids that act as the natural ligands of B-subunits. In practice, an IgG antibody against the A-subunit of a target toxin is selected from commercially available sources and immobilized on the surface of Au nanoparticles to constitute a multivalent IgG/Au nanoconjugate. The derived IgG/Au conjugate is used in the pretreatment process of test samples for deactivating biological toxins in the form of a ternary toxin/antibody/Au complex. This process is implemented in advance to reduce the risk of handling biological toxins in laboratory work. On the other hand, the human glycolipid is immobilized on a tiny glass plate and used as a biosensor chip. The biosensor chip is set in the chamber of a flow sensing system using localized surface plasmon resonance (LSPR) spectrometry available in portable size at relatively low cost. In principle, the LSPR sensing system enables us to perform a rapid and selective detection for different kinds of biological toxins if the human glycolipid is correctly selected and installed in the sensing system. In the present LSPR sensing approach, a target AB toxin may have been deactivated during the pretreatment process. The test sample containing the deactivated AB toxin becomes a real target to be analyzed by the sensing system. In the present, we describe the concept of employing the commercially available IgG antibody in the pretreatment process followed by a typical procedure for converting it into the multivalent antibody/Au nanoconjugate and its preliminary applications in the LSPR detection of a ricin homologue (RCA120) and BoNTs in different serotypes. The tested LSPR sensing approach has worked very well for the ricin homologue and certain serotypes of botulinum neurotoxins like BoNT/A, indicating that the prior deactivation process at their A-domains causes no significant damage to the function of their B-domains with respect to determining the host cell-membrane glycolipid. The experimental results also indicated that LSPR responses from these pretreated AB toxins are significantly amplified. That is obviously thanks to the presence of Au nanoparticles in the multivalent IgG/Au nanoconjugate. We suggest in conclusion that the proposed LSPR sensing approach will provide us with a safe and useful tool for the study of biological AB toxins based on their unique quaternary protein structures.

Hypersensitive Detection and Quantitation of BoNT/A by IgY Antibody Against Substrate Linear-Peptide.

Development of highly sensitive chemiluminescence enzyme immunoassay based on the anti-recombinant H(C) subunit of botulinum neurotoxin type A monoclonal antibodies.

High sensitivity detection of active botulinum neurotoxin by glyco-quantitative polymerase chain-reaction.

High Sensitivity ELISA for Detection of Botulinum Neurotoxin Serotype F.

Detection of Botulinum Neurotoxin A (bont/a) Enzymatic Activity by Pregnancy Test Strips Based on Hcg-Modified Magnetic Nanoparticles

Rapid and sensitive detection of botulinum toxin type A in complex sample matrices by AlphaLISA

Development of an alternative approach for detecting botulinum neurotoxin type A in honey: Analysis of non-toxic peptides with a reference labelled protein via liquid chromatography-tandem mass spectrometry

Neutralizing Antibodies Of Botulinum Neurotoxin Serotype A Screened From A Fully Synthetic Human Antibody Phage Display Library

Validation of a clinical assay for botulinum neurotoxins through mass spectrometric detection

SiO 2 /Si interferometers designed for on-site botulinum neurotoxin serotypes B and C quantification and biological activity assessment

Detection of Active BoNT/C and D by EndoPep-MS Using MALDI Biotyper Instrument and Comparison with the Mouse Test Bioassay

In vitro quantification of botulinum neurotoxin type A1 using immobilized nerve cell-mimicking nanoreactors in a microfluidic platform

Development of a Fusion Protein SNVP As Substrate for Assaying Multi-Serotype Botulinum Neurotoxins.

An Advanced Sensing Approach to Biological Toxins with Localized Surface Plasmon Resonance Spectroscopy Based on Their Unique Protein Quaternary Structures

A New Neutralizing Antibody Against Botulinum Neurotoxin B Recognizes the Protein Receptor Binding Sites for Synaptotagmins II.

Generation of A Recombinant Full-Length Human Antibody Binding to Botulinum Neurotoxin A

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

Botulinum Toxin Type B Micromechanosensor

Plastic enzyme-linked immunosorbent assays (ELISA)-on-a-chip biosensor for botulinum neurotoxin A

Sensitive and Quantitative Detection of Botulinum Neurotoxin in Neurons Derived from Mouse Embryonic Stem Cells

The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo